Shen Joan Hq, Shen Qi, Yu Holly, Lai Jin-Shei, Beaumont Jennifer L, Zhang Zhenxin, Wang Huali, Kim Seong Yoon, Chen Christopher, Kwok Timothy, Wang Shuu-Jiun, Lee Dong Young, Harrison John, Cummings Jeffrey
Pfizer Inc Shanghai, China.
Clinical Science, Pfizer Inc 500 Arcola Rd, Collegeville, PA, USA.
Am J Neurodegener Dis. 2014 Dec 5;3(3):158-69. eCollection 2014.
There is a lack of validated tools for assessing Alzheimer's disease (AD) across Asia. This study evaluates the psychometric properties of the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), Disability Assessment for Dementia (DAD), and Neuropsychological Test Battery (NTB) in Asian participants. Participants with mild to moderate AD (n=251) and healthy controls (n=51) from Mainland China, Taiwan, Singapore, Hong Kong, and South Korea completed selected instruments at several time points. Test-retest reliability was better than 0.70 for all tests. AD participants performed significantly more poorly than controls on every score. Within the AD group, greater disease severity corresponded to significantly poorer performance. The AD group test performance worsened over time and there was a trend for worse performance in AD compared to healthy controls over time. The ADAS-Cog, DAD, and NTB are reliable, valid, and responsive measures in this population and could be used for clinical trials across Asian countries/regions.
在亚洲，缺乏经过验证的用于评估阿尔茨海默病（AD）的工具。本研究评估了阿尔茨海默病评估量表认知子量表（ADAS-Cog）、痴呆残疾评估量表（DAD）和神经心理测试组合（NTB）在亚洲参与者中的心理测量特性。来自中国大陆、台湾、新加坡、中国香港和韩国的轻度至中度AD患者（n = 251）和健康对照者（n = 51）在多个时间点完成了选定的测评工具。所有测试的重测信度均优于0.70。AD患者在各项得分上的表现均显著差于对照组。在AD组中，疾病严重程度越高，表现越差。AD组的测试表现随时间推移而恶化，且随着时间的推移，AD患者与健康对照者相比有表现更差的趋势。ADAS-Cog、DAD和NTB在该人群中是可靠、有效的且具有反应性的测量工具，可用于亚洲国家/地区的临床试验。
